Class summary at a glance.

Every drug in the Glycopeptide Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $75.0Mcombined across class
Total Rx claims: 571K273K unique beneficiaries
Generic mfrs (active): 21across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Vancomycin

Brand: FIRVANQ · 571K Part D claims (CY24) · 273K beneficiaries · First FDA approval: 1958-11-14

21 generic mfrs 55 plans require PA Discontinued

Low NADAC$0.387

→

Avg plan cost$1.69

Part D spend $75.0M 4× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.